P. Hugh R. Barrett - Search Results

Year	Number of Results
2002	19
2003	12
2004	10
2005	12
2006	14
2007	11
2008	13
2009	5
2010	7
2011	4
2012	6
2013	9
2014	7
2015	10
2016	8
2017	4
2018	6
2019	3
2020	1
2021	2
2022	1

1

Unravelling lipoprotein metabolism with stable isotopes: tracing the flow.

Ying Q, Chan DC, Barrett PHR, Watts GF. Ying Q, et al. Among authors: barrett phr. Metabolism. 2021 Nov;124:154887. doi: 10.1016/j.metabol.2021.154887. Epub 2021 Sep 8. Metabolism. 2021. PMID: 34508741 Review.

2

Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterol-Lowering Therapy.

Chan DC, Watts GF, Coll B, Wasserman SM, Marcovina SM, Barrett PHR. Chan DC, et al. Among authors: barrett phr. J Am Heart Assoc. 2019 Apr 2;8(7):e011781. doi: 10.1161/JAHA.118.011781. J Am Heart Assoc. 2019. PMID: 30897995 Free PMC article. Clinical Trial.

3

Genetic determinants of apolipoprotein B-100 kinetics.

Ng TW, Ooi EM, Watts GF, Chan DC, Barrett PH. Ng TW, et al. Among authors: barrett ph. Curr Opin Lipidol. 2010 Apr;21(2):141-7. doi: 10.1097/MOL.0b013e3283378e5a. Curr Opin Lipidol. 2010. PMID: 20154610 Review.

4

Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism.

Watts GF, Chan DC, Dent R, Somaratne R, Wasserman SM, Scott R, Burrows S, R Barrett PH. Watts GF, et al. Among authors: r barrett ph. Circulation. 2017 Jan 24;135(4):338-351. doi: 10.1161/CIRCULATIONAHA.116.025080. Epub 2016 Dec 9. Circulation. 2017. PMID: 27941065 Clinical Trial.

5

Postprandial dyslipidaemia and diabetes: mechanistic and therapeutic aspects.

Pang J, Chan DC, Barrett PH, Watts GF. Pang J, et al. Among authors: barrett ph. Curr Opin Lipidol. 2012 Aug;23(4):303-9. doi: 10.1097/MOL.0b013e328354c790. Curr Opin Lipidol. 2012. PMID: 22595742 Review.

6

The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia.

Chan DC, Barrett PH, Watts GF. Chan DC, et al. Among authors: barrett ph. Best Pract Res Clin Endocrinol Metab. 2014 Jun;28(3):369-85. doi: 10.1016/j.beem.2013.10.001. Epub 2013 Oct 9. Best Pract Res Clin Endocrinol Metab. 2014. PMID: 24840265 Review.

7

Apolipoprotein(a) Kinetics in Statin-Treated Patients With Elevated Plasma Lipoprotein(a) Concentration.

Ma L, Chan DC, Ooi EMM, Marcovina SM, Barrett PHR, Watts GF. Ma L, et al. Among authors: barrett phr. J Clin Endocrinol Metab. 2019 Dec 1;104(12):6247-6255. doi: 10.1210/jc.2019-01382. J Clin Endocrinol Metab. 2019. PMID: 31393573

8

Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose-response model.

Jadhav SB, Crass RL, Chapel S, Kerschnitzki M, Sasiela WJ, Emery MG, Amore BM, Barrett PHR, Watts GF, Catapano AL. Jadhav SB, et al. Among authors: barrett phr. Eur Heart J Cardiovasc Pharmacother. 2021 Aug 27:pvab064. doi: 10.1093/ehjcvp/pvab064. Online ahead of print. Eur Heart J Cardiovasc Pharmacother. 2021. PMID: 34448822

9

Effect of weight loss on HDL-apoA-II kinetics in the metabolic syndrome.

Ng TW, Chan DC, Barrett PH, Watts GF. Ng TW, et al. Among authors: barrett ph. Clin Sci (Lond). 2009 Oct 2;118(1):79-85. doi: 10.1042/CS20090110. Clin Sci (Lond). 2009. PMID: 19456294 Free PMC article. Clinical Trial.

10

Dietary fatty acids and lipoprotein metabolism: new insights and updates.

Ooi EM, Ng TW, Watts GF, Barrett PH. Ooi EM, et al. Among authors: barrett ph. Curr Opin Lipidol. 2013 Jun;24(3):192-7. doi: 10.1097/MOL.0b013e3283613ba2. Curr Opin Lipidol. 2013. PMID: 23619368 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results